Kategori: Forskning

Roche/ Genentech uppdaterar GENERATION HD2-studien

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis avslutar VIBRANT-HD-studien

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

uniQure meddelade att de återupptar rekryteringen av patienter på den högre dosnivån i AMT-130-studien.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences meddelar en positiv uppdatering från fas 1b/2a SELECT-HD-studien med inledande resultat som indikerar att WVE-003 har ett allelselektivt mål för Huntingtons sjukdom

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure meddelar uppdatering av kohort med låg dos i klinisk fas I/II-studie av AMT-130 genterapi för behandling av Huntingtons sjukdom

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences uppdaterar resultaten från studierna

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinar - Allt du behöver veta om Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Breaking News - Roche planerar en ny Tominersen-studie

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]